- Home
- NXGL vs ALUR Comparison
NXGL vs ALUR Comparison
Compare NXGL & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- ALUR
- Stock Information
- Founded
- NXGL 1997
- ALUR 2009
- Country
- NXGL United States
- ALUR United States
- Employees
- NXGL N/A
- ALUR N/A
- Industry
- NXGL Medical/Dental Instruments
- ALUR
- Sector
- NXGL Health Care
- ALUR
- Exchange
- NXGL Nasdaq
- ALUR Nasdaq
- Market Cap
- NXGL 18.7M
- ALUR 15.4M
- IPO Year
- NXGL 2021
- ALUR N/A
- Fundamental
- Price
- NXGL $2.45
- ALUR $1.85
- Analyst Decision
- NXGL
- ALUR Buy
- Analyst Count
- NXGL 0
- ALUR 2
- Target Price
- NXGL N/A
- ALUR $9.25
- AVG Volume (30 Days)
- NXGL 65.2K
- ALUR 52.9K
- Earning Date
- NXGL 11-10-2025
- ALUR 11-13-2025
- Dividend Yield
- NXGL N/A
- ALUR N/A
- EPS Growth
- NXGL N/A
- ALUR N/A
- EPS
- NXGL N/A
- ALUR N/A
- Revenue
- NXGL $11,672,000.00
- ALUR $19,917,000.00
- Revenue This Year
- NXGL $46.60
- ALUR N/A
- Revenue Next Year
- NXGL $47.96
- ALUR N/A
- P/E Ratio
- NXGL N/A
- ALUR N/A
- Revenue Growth
- NXGL 133.02
- ALUR N/A
- 52 Week Low
- NXGL $2.10
- ALUR $1.83
- 52 Week High
- NXGL $5.10
- ALUR $19.69
- Technical
- Relative Strength Index (RSI)
- NXGL 44.97
- ALUR 35.23
- Support Level
- NXGL $2.45
- ALUR $1.85
- Resistance Level
- NXGL $2.71
- ALUR $2.03
- Average True Range (ATR)
- NXGL 0.18
- ALUR 0.11
- MACD
- NXGL -0.01
- ALUR -0.01
- Stochastic Oscillator
- NXGL 24.53
- ALUR 8.57
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.